These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 19720636)
1. A BEAUTIFUL lesson--ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Heusch G Eur Heart J; 2009 Oct; 30(19):2300-1. PubMed ID: 19720636 [No Abstract] [Full Text] [Related]
2. Left ventricular remodelling in systolic heart failure using ivabradine. Slower is smaller is better? Fruhwald F; Pieske B Eur Heart J; 2011 Oct; 32(20):2481-2. PubMed ID: 21875857 [No Abstract] [Full Text] [Related]
3. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R; Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635 [TBL] [Abstract][Full Text] [Related]
4. Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias. Ng FS; Shadi IT; Peters NS; Lyon AR J Mol Cell Cardiol; 2013 Jun; 59():67-75. PubMed ID: 23402927 [TBL] [Abstract][Full Text] [Related]
5. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Fox K; Ferrari R; Tendera M; Steg PG; Ford I; Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146 [TBL] [Abstract][Full Text] [Related]
6. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Castagno D; Petrie MC; Claggett B; McMurray J Eur Heart J; 2012 May; 33(9):1137-41. PubMed ID: 22408030 [TBL] [Abstract][Full Text] [Related]
7. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. ; Ferrari R; Ford I; Fox K; Steg PG; Tendera M Cardiology; 2008; 110(4):271-82. PubMed ID: 18595216 [TBL] [Abstract][Full Text] [Related]
8. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Fox K; Ford I; Steg PG; Tendera M; Ferrari R; Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088 [TBL] [Abstract][Full Text] [Related]
9. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611 [TBL] [Abstract][Full Text] [Related]
10. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Canet E; Lerebours G; Vilaine JP Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947 [TBL] [Abstract][Full Text] [Related]
12. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K; Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517 [TBL] [Abstract][Full Text] [Related]
13. Limited role for ivabradine in the treatment of chronic heart failure. Cullington D; Goode KM; Cleland JG; Clark AL Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660 [TBL] [Abstract][Full Text] [Related]
14. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study]. Filipovský J Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618 [TBL] [Abstract][Full Text] [Related]
15. Rate control with ivabradine: angina pectoris and beyond. Parakh N; Bhargava B Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826 [TBL] [Abstract][Full Text] [Related]
16. Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias. Mert KU; Mert GÖ; Morrad B; Tahmazov S; Mutlu F; Çavuşoglu Y Kardiol Pol; 2017; 75(8):786-793. PubMed ID: 28541596 [TBL] [Abstract][Full Text] [Related]
17. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction. Heusch G; Kleinbongard P Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289 [TBL] [Abstract][Full Text] [Related]
18. [Ivabradine in coronary heart disease: experimental and clinical pharmacology]. Pathak A; Berdeaux A; Mulder P; Thuillez C Therapie; 2010; 65(5):483-9. PubMed ID: 21144484 [TBL] [Abstract][Full Text] [Related]
19. New data support ivabradine use in chronic heart failure. Aalbers J Cardiovasc J Afr; 2011; 22(4):216-7. PubMed ID: 21881692 [No Abstract] [Full Text] [Related]
20. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study. Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]